Gilead Sciences Inc. is paying Korean firm LG Life Sciences Ltd. $20 million up front for rights to a caspase inhibitor program for fibrotic diseases, which includes a Phase II-stage compound being tested in patients with hepatitis C virus. (BioWorld Today) Read More
